Login to Your Account

Afinitor shown to delay tumor growth in HER2+ advanced breast cancer

By John Fox
Staff Writer

Wednesday, June 4, 2014

HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2) positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers report.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription